Public Health Emergency of International Concern (PHEIC)
Situation report – 187
Coronavirus disease 2019 (COVID-19)
25 July 2020
Confirmed cases :: 15 581 009 [week ago: 13 876 441]
Confirmed deaths :: 635 173 [week ago: 593 087]
:: The COVID-19 pandemic has affected older people disproportionately, especially those living in long-term care facilities. WHO has published a policy brief on preventing and managing COVID-19 across long-term care services.
:: WHO has released a set of practical steps for implementing the prescriptions of the WHO Manifesto for a healthy recovery from COVID-19. These prescriptions aim to create a healthier, fairer and greener world while investing to maintain and resuscitate the economy hit by the effects of the pandemic.
New COVID-19 Law Lab to provide vital legal information and support for the global COVID-19 response
22 July 2020 News release New York/Geneva
Launching today, the COVID-19 Law Lab initiative gathers and shares legal documents from over 190 countries across the world to help states establish and implement strong legal frameworks to manage the pandemic. The goal is to ensure that laws protect the health and wellbeing of individuals and communities and that they adhere to international human rights standards.
The new Lab (at www.COVIDLawLab.org) is a joint project of United Nations Development Programme (UNDP), the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the O’Neill Institute for National and Global Health Law at Georgetown University.
Well-designed laws can help build strong health systems; evaluate and approve safe and effective drugs and vaccines; and enforce actions to create healthier and safer public spaces and workplaces. Critically, they are key to effective implementation of the WHO International Health Regulations: surveillance; infection prevention and control; management of travel and trade; and implementation of measures to maintain essential health services.
“Laws and policies that are grounded in science, evidence and human rights can enable people to access health services, protect themselves from COVID-19 and live free from stigma, discrimination and violence,” says Achim Steiner, UNDP Administrator. “The COVID-19 Law Lab is an important tool for sharing good practices on laws and policies.”…
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
July 22, 2020
:: U.S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional doses
:: Americans to receive the vaccine for free consistent with U.S. government’s commitment for free access for COVID-19 vaccines
:: Pfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as October 2020, and manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
July 20, 2020
:: The data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV-2 neutralizing titers
:: BNT162b1 elicited strong CD4+ and CD8+ T cell responses against SARS-CoV-2- receptor binding domain (RBD), compared to baseline
:: The RBD-specific, interferon-γ+, IL-2+, CD8+ T cells elicited by BNT162b1 in immunized participants indicate a strong potential for cell mediated anti-viral activity
:: T cell cytokine profile shows vaccine elicited T cells exhibit a Th1 phenotype, which is associated with antiviral properties
:: BNT162b1 induced antibodies had broadly neutralizing activity in pseudovirus neutralization assays across a panel of sixteen SARS-CoV-2 RBD variants identified in published SARS-CoV-2 sequences and against the newly dominant D614G strain
:: Robust specific antibody and T cell responses, (both of which are considered by experts as key to a vaccine ensuring protection against disease) elicited by the BNT162b1 mRNA vaccine against RBD suggest a potential for multiple beneficial protective mechanisms against COVID-19
:: Local reactions and systemic events after immunization with BNT162b1 were dose-dependent, generally mild to moderate and transient, with occasional severe adverse events (Grade 3, e.g. flu-like symptoms and injection site reactions) that resolved spontaneously or could be managed with simple measures – no serious adverse events were reported
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
July 19, 2020
:: Thirty million doses expected to be delivered in 2020 and 2021, subject to regulatory approval or authorization
:: Pfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and efficacy trial later this month, seek regulatory review as early as October 2020 and manufacture globally up to 100 million doses by the end of 2020 and more than 1.3 billion doses by the end of 2021
:: Agreement is part of Pfizer’s and BioNTech’s global commitment to help address the pandemic